ProBioGen and LAVA Therapeutics have announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA's pipeline.
Under the agreement and using its CHO.RiGHT expression platform, including DirectedLuck Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line development of a novel gamma-delta bsTCE.
"We are delighted to continue our collaboration with LAVA to develop cell lines for another novel gamma-delta bsTCE. Our proven cell line development platform, which also includes our Transposase technology, is perfectly suited for novel protein formats", said ProBioGen's CEO Dr Lutz Hilbrich.
"Based on the great results from our previous agreement, we would look forward working with ProBioGen again", commented Stephen Hurly, CEO and President of LAVA Therapeutics. "ProBioGen exceeded our expectations and proved to be a scientifically driven partner with a proven development platform and a dedicated analytical panel for bispecific antibody formats."
